Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: donepezil HCL Clear all

Conditions: Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions: vitamin E, donepezil hydrochloride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more

Conditions: Alzheimer Disease
Interventions: Donepezil, Estrogen, Progesterone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Alzheimer's Disease
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more

Conditions: Brain and Central Nervous System Tumors, Radiation Toxicity
Interventions: EGb761, donepezil hydrochloride, cognitive assessment; Dietary Supplement · Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 4
States / cities: Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more

Conditions: Wound Heal
Interventions: Donepezil, Placebo oral tablet, Topical Zinc Oxide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Skin Irritation, Sensitization
Interventions: Donepezil TDS, Vehicle TDS; Drug
Lead sponsor: Corium, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Alzheimer Disease
Interventions: Donepezil, Vitamin E; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more

Conditions: Ischemic Stroke
Interventions: donepezil, placebo; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Warren, Ohio • Pittsburgh, Pennsylvania

Conditions: Postoperative Complications, Delirium
Interventions: Donepezil; Drug
Lead sponsor: Indiana University Health; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Brain Tumors, Metastatic Disease
Interventions: donepezil hydrochloride, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 16
States / cities: Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Bilateral Sensorineural Hearing Loss
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alzheimer's Disease
Interventions: PF-03654746, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Alzheimer's Disease
Interventions: donezepil (Aricept); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New Haven, Connecticut • Albany, New York

Conditions: Alzheimer's Disease
Interventions: RVT-101 35 mg tablets; Drug
Lead sponsor: Axovant Sciences Ltd.; Industry
Eligibility: 50 Years to 86 Years
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more

Conditions: Alzheimer Disease
Interventions: BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo comparator; Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 52
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more

Conditions: Visual Perception, Attention, Information Processing, Cholinergic System
Interventions: Donepzil, Placebo oral tablet; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Fragile X Syndrome
Interventions: donepezil, sugar pill; Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 29 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alzheimer Disease
Interventions: Aricept, Exelon, Nicoderm Patch; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cocaine Use Disorders
Interventions: High-dose donepezil, Low-dose donepezil, Selegiline, Placebo; Drug
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 21 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Alzheimer's Disease
Interventions: VI-1121, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more

Conditions: Stroke, Vascular Dementia, Memory Deficits
Interventions: Donepezil and self-generated memory training, Donepezil and experimenter-administered memory training; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: West Orange, New Jersey

Search by objective public record fields.

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

The Effect of Donepezil on Wound Healing

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

Memory Impairment Study (Mild Cognitive Impairment Study)

Enhancing Rehabilitation After Stroke

Donepezil in Preventing Delirium in Hospitalized Elderly

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

TAK-071 Scopolamine-Induced Cognitive Impairment Study

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

Randomized Controlled Study of Donepezil in Fragile X Syndrome

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

VI-1121 for the Treatment Alzheimer's Disease

Aricept to Improve Functional Tasks in Vascular Dementia